Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Liu D
Authors: Liu D, Fath M, Robles Planells C, Balk E, Bellizzi A,
Keywords: CXCR4, thioredoxin reductase inhibitor, theranostics, atypical carcinoid, small cell lung cancer,
Introduction: Neuroendocrine carcinomas (NECs) are a rare subgroup of neuroendocrine neoplasms that occasionally originate from gastro-entero-pancreatic (GEP) tract. Owing to their low incidence, evidences of the effectiveness of chemotherapy are scarce. Analogously to small cell lung cancer, platinum plus etoposide (Vp16) regimens are currently the standard treatment in first-line, while little data are available on the role of second-line treatment.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Bardasi C, Caputo F, Santini C, Cerma K, Casadei Gardini A,
Keywords: neuroendocrine carcinoma, irinotecan, survival, second line treatment, NEC, chemotherapy,
Introduction: High grade Neuroendocrine Neoplasias (NEN) are rare tumors with a poor prognosis and no established second line therapy.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Weber M
Authors: Fottner C, Apostolidis L, Ferrata M, Krug S, Michl P,
Keywords: NEC, NEN G3, check-point inhibitor, Avelumab, anti-PD-L1-antibody, immunotherapy,
#2154 Clinical and Morphological Features of Extrapulmonary Small-Cell Cancer
Introduction: Extrapulmonary Small-cell cancer (ESCC) is an extremely rare disease. Usually in the treatment of patients with ESCC approaches to the treatment of patients with small cell lung cancer (SCLC) are used.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Ivanov A, Gorbunova V, Delektorskaya V, Kuzminov A,
Keywords: small cell cancer, Extrapulmonary small cell cancer, somatostatin receptors,
Introduction: Advanced neuroendocrine carcinomas (NEC) of the lung are associated with a dismal prognosis and are commonly treated with platinum/etoposide (P/E) regimens. However, few studies evaluated their impact in lung NEC and it is still unclear whether the outcome of such patients (pts) has been improved over the past years (yrs).
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Giuffrida D
Authors: Giuffrida D, Chillari F, Blanco G, Russo A, Franchina T,
Keywords: neuroendocrine carcinoma, lung, platinum-etoposide, LCNEC, SCLC, chemotherapy,